Physician profile
Stephanie E Averette
NPI 1124113170
$5,625.69
in general payments reported to CMS, 2019-2025
19 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,230 · 2022: $1,482 · 2023: $1,742 · 2024: $791 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.80 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,129.82 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $890.53 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $689.38 | 2022-2025 | Ingrezza |
| Abbvie INC. | $414.30 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $310.33 | 2021-2023 | |
| Gilead Sciences, INC. | $250.55 | 2022-2023 | Epclusa |
| Insmed, INC. | $229.18 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $222.94 | 2022 | |
| Abbott Laboratories | $218.04 | 2022-2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $207.60 | 2024-2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $207.04 | 2021 | |
| Argenx US, INC. | $131.71 | 2023 | Vyvgart |
| Idorsia Pharmaceuticals US INC | $124.87 | 2024 | Quviviq |
| Genzyme Corporation | $124.80 | 2024 | |
| Mylan Specialty L.P. | $123.39 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.54 | 2024 | Cobenfy |
| Cvrx, INC. | $88.09 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $84.61 | 2025 | |
| Genentech USA, INC. | $61.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Averette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.